9939 — Kintor Pharmaceutical Cashflow Statement
0.000.00%
Last trade - 00:00- HK$1.32bn
- HK$1.38bn
- CNY32.68m
Annual cashflow statement for Kintor Pharmaceutical, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | — |
| Source: | ARS | ARS | ARS | ARS | |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | fx Preliminary |
| Net Income/Starting Line | -842 | -953 | -1,069 | -155 | — |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 66.5 | 173 | 761 | -6.46 | — |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -286 | -199 | -98.7 | -55 | — |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -1,051 | -961 | -388 | -199 | — |
| Capital Expenditures | -106 | -27.6 | -2.72 | -1.68 | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 198 | 94.8 | 6 | 21.7 | — |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 92 | 67.2 | 3.27 | 20 | — |
| Financing Cash Flow Items | -2.03 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 857 | 816 | -33.5 | -120 | — |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -138 | -61.9 | -420 | -297 | — |